DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis

Company Overview

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for acute and chronic conditions in neurology, ophthalmology and cardio-renal medicine. The company’s lead candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to address unmet medical needs in acute ischemic stroke, neurodegenerative diseases and renal impairment. DiaMedica’s research efforts focus on leveraging the unique properties of tissue kallikrein pathways to promote tissue repair, reduce inflammation and improve functional outcomes following injury.

DiaMedica’s pipeline is anchored by DM199, which is currently being evaluated in multiple Phase II clinical trials. A key program investigates the potential of DM199 to reduce the extent of brain injury and improve neurological recovery in patients suffering from ischemic stroke. In parallel, the company is exploring the application of its kallikrein platform in chronic kidney disease and eye disorders, aiming to expand the therapeutic scope of its lead molecule. DiaMedica complements its core development activities with preclinical research on novel indications and formulations to maximize patient benefit.

Founded in 2013 and headquartered in Minneapolis, Minnesota, DiaMedica has established operations in both the United States and Europe, enabling collaborations with leading academic centers and contract research organizations. The company pursues strategic partnerships and licensing agreements to access complementary technologies and accelerate clinical development. DiaMedica’s management team combines industry veterans with scientific experts in drug discovery, clinical development and regulatory affairs to advance its programs efficiently through global regulatory pathways.

Under the leadership of President and CEO Donna R. Cambareri, DiaMedica has built a lean organizational structure designed to adapt quickly to evolving scientific and clinical landscapes. The company’s strategy emphasizes rigorous clinical evaluation, risk-adjusted investment in pipeline programs and transparent engagement with regulators, investors and patient advocacy groups. As DiaMedica advances its clinical candidates toward pivotal studies, it remains focused on delivering transformative therapies for serious medical conditions with high unmet need.

Key Stats

• Today's Range: $3.65 to $3.88
• 50-Day Range: $3.51 to $4.27
• 52-Week Range: $2.98 to $6.82
• Volume: 261,167 shs
• Average Volume: 101,327 shs
• Market Capitalization: $165.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

DiaMedica Therapeutics Stock Analysis - MarketRank™

DiaMedica Therapeutics scored higher than 22% of companies evaluated by MarketBeat, and ranked 850th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

DiaMedica Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

DiaMedica Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for DiaMedica Therapeutics are expected to decrease in the coming year, from ($0.59) to ($0.80) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DiaMedica Therapeutics is -6.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of DiaMedica Therapeutics is -6.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

DiaMedica Therapeutics has a P/B Ratio of 4.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.09% of the float of DiaMedica Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

DiaMedica Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.

Change versus previous month

Short interest in DiaMedica Therapeutics has recently increased by 11.82%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DiaMedica Therapeutics does not currently pay a dividend.

Dividend Growth

DiaMedica Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.09% of the float of DiaMedica Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

DiaMedica Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.

Change versus previous month

Short interest in DiaMedica Therapeutics has recently increased by 11.82%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, DiaMedica Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.30% of the stock of DiaMedica Therapeutics is held by insiders.

Percentage Held by Institutions

Only 10.12% of the stock of DiaMedica Therapeutics is held by institutions.

DMAC Stock Analysis - Frequently Asked Questions

How have DMAC shares performed this year?

DiaMedica Therapeutics' stock was trading at $5.43 at the beginning of the year. Since then, DMAC stock has decreased by 29.1% and is now trading at $3.85.

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) posted its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.18).
Read the conference call transcript.

When did DiaMedica Therapeutics IPO?

DiaMedica Therapeutics (DMAC) raised $18 million in an initial public offering on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DiaMedica Therapeutics investors own include NVIDIA (NVDA), ADMA Biologics (ADMA), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX), Ardelyx (ARDX) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DMAC
• CIK: 1401040
• Web: www.diamedica.com
• Phone: (763) 496-5454
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for DiaMedica Therapeutics: $8.00
• High Price Target: $10.00
• Low Price Target: $6.00
• Potential Upside/Downside: +107.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -61.35%
• Return on Assets: -55.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.02
• Quick Ratio: 8.02

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.95 per share
• Price / Book: 4.05

Miscellaneous

• Outstanding Shares: 42,883,000
• Free Float: 39,753,000
• Market Cap: $165.10 million
• Optionable: Optionable
• Beta: 1.17